CMRX: Chimerix Inc. Short-Term Debt to Equity

Chimerix, Inc. - graphic logo of issuer CMRX

Chimerix, Inc. (CMRX) develops antitumor agents utilizing an advanced cooling system for component transport, as confirmed by this price chart. The business relies on government agreements for antiviral products to establish a foundation for oncology research, with the indicator standing at 0.01. Growth depends on drug trials for bone marrow transplant patients and the efficient management of R&D expenses.

CMRX (Chimerix, Inc) Current Liabilities to Capital history from 07/04/2022 to 04/26/2025

Analytical breakdowns for chimerix.com (CMRX)

- price and consensus price forecast:
Stock Price Chimerix, Inc|CMRX - Average Forecast Price
- market capitalization data:
Market Value Chimerix Inc.|CMRX - Business Value
- book capitalization data:
Book Value per Share Chimerix|CMRX - Total Stockholders' Equity|Market Value to Book Value Ratio chimerix.com|CMRX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Chimerix, Inc.|CMRX - Long-Term Debt to Capital|Short-Term Debt to Equity Chimerix|CMRX - Company Debts|Debt to Book Value Chimerix Inc.|CMRX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Chimerix
Fundamental company analysis:Chimerix, Inc.
Brand item of Chimerix

This ratio compares liabilities with a maturity of up to one year against total capital, revealing the firm's reliance on short-term borrowing to cover operating expenses. An increase in this metric signals liquidity risk, which is critical for Chimerix, Inc. (CMRX) when financing the development of oncology drugs; therefore, the trend of the short-term debt-to-capital ratio serves as an indicator of financial stability between partner payments.

Competing companies

Incyte Corp. - Short-Term Debt to Capital|Current Liabilities to Capital HCM (HUTCHMED Corp)|NUVB - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio dayonebio.com DAWN|MNPR (Monopar Therapeutics Inc.) - Short-Term Debt to Capital|INBX: Current Liabilities to Capital|Short-Term Debt to Equity i-mabbiopharma.com IMAB|Fennec (FENC) - Ratio of Short-Term Indebtedness to Capital|HRTX (Heron) - Short-Term Debt to Capital|Short-Term Debt to Capital NVCT|Short-Term Debt to Equity Coherus BioSciences, Inc (CHRS)|Short-Term Debt to Equity Corbus Pharmaceuticals Holdings, Inc. CRBP|Short-Term Debt to Equity Ratio Cardiff Oncology|BeyondSpring Inc - Ratio of Short-Term Indebtedness to Capital|BCAB (BioAtla Corp) - Short-Term Debt to Equity|LIXT: Current Liabilities to Capital|Short-Term Debt to Equity citiuspharma.com|Cellectar Biosciences Inc (CLRB) - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital BLRX|Short-Term Debt to Equity Ratio CANF|Aprea Therapeutics - Short-Term Debt to Equity|Current Liabilities to Capital KZIA (kaziatherapeutics.com)|Short-Term Debt to Equity Silexion Therapeutics SLXN|NuCana PLC - Short-Term Debt to Equity|CYCC (Cyclacel Pharmaceuticals Inc.) - Short-Term Debt to Equity|GTHX - Current Liabilities to Capital|Short-Term Debt to Capital KRON (Kronos Bio, Inc.)|Short-Term Indebtedness to Equity kintara.com|Short-Term Debt to Equity Ratio ONCT (Oncternal Therapeutics, Inc.)|Current Liabilities to Capital Portage Biotech Inc (PRTG)